Ellen M. Howerton
Research Subjects
Ellen M. Howerton has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
M. Daniele Fallin
Emory University
2 shared publications- Anne V. Kirby
Department of Occupational and Recreational Therapies, University of Utah, Salt Lake City, UT, USA
1 shared publication Barry Zuckerman
Boston Medical Center
1 shared publicationBrion Maher
Johns Hopkins University
1 shared publication- Carolyn DiGuiseppi
University of Colorado Anschutz, Aurora, USA
1 shared publication Christine Ladd-Acosta
Wendy Klag Center for Autism and Developmental Disabilities, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
1 shared publication
Latest Publications
- Open Access
- 24 March 2026
- Published by Springer Nature in Journal of Autism and Developmental Disorders
Prevalence of Autism Spectrum Disorder Severity Levels From the Fifth Edition of the Diagnostic and Statistical Manual (DSM-5) in the Autism and Developmental Disabilities Monitoring Network
Purpose: The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) introduced severity level specifiers for autism spectrum disorder (ASD) with minimal description of the criteria for categorizing three levels of severity (1 to 3, with 3 being the most “severe”). The objective of the analysis was to assess the prevalence of ASD severity levels using population-based surveillance data. Methods: We analyzed severity level data on children with ASD ages 4- and 8-years-old in 2018 and 2020 in the multisite Autism and Developmental Disabilities Monitoring (ADDM) Network. Prevalence of any documented severity level and of each individual level were calculated overall and by demographic characteristics. Prevalence ratios adjusted for sex, race/ethnicity, age, intellectual disability, ADDM surveillance year, and site (aPRs) and 95% confidence intervals (CIs) were used for comparisons. Results: Less than half (40.4%) of children with documented ASD diagnoses had any severity level specified in their records, with wide variation by site (4.8%-73.2%). Severity levels were more common in records of children aged 4, in surveillance year 2020, and more often missing in non-Hispanic Black children and from records also missing information on intellectual disability (ID). Higher prevalence of more severe (level 3) ASD was observed among non-Hispanic Black children, children aged 4 years, children in 2020, and children with ID. Conclusion: Utilization of the DSM-5’s severity levels by community professionals varied widely, limiting their potential utility in identifying needed services and supports for children with ASD.
- 24 March 2026
- Published by Springer Nature in Journal of Autism and Developmental Disorders
Open AccessPrevalence of Autism Spectrum Disorder Severity Levels From the Fifth Edition of the Diagnostic and Statistical Manual (DSM-5) in the Autism and Developmental Disabilities Monitoring Network
Purpose: The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) introduced severity level specifiers for autism spectrum disorder (ASD) with minimal description of the criteria for categorizing three levels of severity (1 to 3, with 3 being the most “severe”). The objective of the analysis was to assess the prevalence of ASD severity levels using population-based surveillance data. Methods: We analyzed severity level data on children with ASD ages 4- and 8-years-old in 2018 and 2020 in the multisite Autism and Developmental Disabilities Monitoring (ADDM) Network. Prevalence of any documented severity level and of each individual level were calculated overall and by demographic characteristics. Prevalence ratios adjusted for sex, race/ethnicity, age, intellectual disability, ADDM surveillance year, and site (aPRs) and 95% confidence intervals (CIs) were used for comparisons. Results: Less than half (40.4%) of children with documented ASD diagnoses had any severity level specified in their records, with wide variation by site (4.8%-73.2%). Severity levels were more common in records of children aged 4, in surveillance year 2020, and more often missing in non-Hispanic Black children and from records also missing information on intellectual disability (ID). Higher prevalence of more severe (level 3) ASD was observed among non-Hispanic Black children, children aged 4 years, children in 2020, and children with ID. Conclusion: Utilization of the DSM-5’s severity levels by community professionals varied widely, limiting their potential utility in identifying needed services and supports for children with ASD.
- Open Access
- 6 December 2022
- Published by Springer Nature in Research Square
Association of prenatal exposure to opioids, cannabis, and polysubstance use with cord blood DNA methylation patterns in a multiancestry cohort
Background: Blood DNA methylation patterns are highly predictive of prenatal exposure to smoking and differential methylation has been associated with maternal alcohol use. We extended this to determine whether DNA methylation patterns in cord blood are associated with prenatal exposure to opioid, cannabis, and polysubstance use. We also evaluated whether DNA methylation patterns have predictive utility. Methods: We examined 932 mother-child pairs in the Boston Birth Cohort between 1998-2020 with cord blood DNA methylation and maternal substance use data. For each substance, we performed adjusted linear regression analysis at 865,859 CpG sites to identify related methylation changes. We generated scores using summary statistics for each exposure and assessed predictive ability using cross-validation and receiver operating characteristic curves. Specificity of methylation associations was evaluated by assessing overlap across exposure summary statistics, and using logistic regression for methylation scores, adjusted for concurrent use. Results: We identified methylation changes at 72, 21, and 1 novel CpG associated with prenatal exposure to opioids, cannabis, and polysubstance use respectively, at epigenome-wide significance (PConclusion: We identified novel DNA methylation differences in cord blood associated with prenatal exposure and showed that methylation scores are highly predictive of substance exposures. These CpGs provide biologic insights for reducing the impact of substance exposure. These findings may serve as a biomarker of prenatal substance exposure for future studies and potential clinical utility.
- 6 December 2022
- Published by Springer Nature in Research Square
Open AccessAssociation of prenatal exposure to opioids, cannabis, and polysubstance use with cord blood DNA methylation patterns in a multiancestry cohort
Background: Blood DNA methylation patterns are highly predictive of prenatal exposure to smoking and differential methylation has been associated with maternal alcohol use. We extended this to determine whether DNA methylation patterns in cord blood are associated with prenatal exposure to opioid, cannabis, and polysubstance use. We also evaluated whether DNA methylation patterns have predictive utility. Methods: We examined 932 mother-child pairs in the Boston Birth Cohort between 1998-2020 with cord blood DNA methylation and maternal substance use data. For each substance, we performed adjusted linear regression analysis at 865,859 CpG sites to identify related methylation changes. We generated scores using summary statistics for each exposure and assessed predictive ability using cross-validation and receiver operating characteristic curves. Specificity of methylation associations was evaluated by assessing overlap across exposure summary statistics, and using logistic regression for methylation scores, adjusted for concurrent use. Results: We identified methylation changes at 72, 21, and 1 novel CpG associated with prenatal exposure to opioids, cannabis, and polysubstance use respectively, at epigenome-wide significance (PConclusion: We identified novel DNA methylation differences in cord blood associated with prenatal exposure and showed that methylation scores are highly predictive of substance exposures. These CpGs provide biologic insights for reducing the impact of substance exposure. These findings may serve as a biomarker of prenatal substance exposure for future studies and potential clinical utility.
- Open Access
- 14 April 2021
- Published by Elsevier in Biological Psychiatry
- Vol. 90 (4) , 253-262
Maternal Psychiatric Conditions, Treatment With Selective Serotonin Reuptake Inhibitors, and Neurodevelopmental Disorders
- 14 April 2021
- Published by Elsevier in Biological Psychiatry
- Vol. 90 (4) , 253-262
Open AccessMaternal Psychiatric Conditions, Treatment With Selective Serotonin Reuptake Inhibitors, and Neurodevelopmental Disorders